Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

mAbs

Volumn 7, Issue 2, 2015, Pages 311-320

  Overdijk, Marije B ^a   Verploegen, Sandra ^a   Bögels, Marijn ^b   Van Egmond, Marjolein ^b   Lammerts Van Bueren, Jeroen J ^a   Mutis, Tuna ^c   Groen, Richard W J ^c   Breij, Esther ^a   Martens, Anton C M ^c   Bleeker, Wim K ^a   Parren, Paul Whi ^d,e  

^a GENMAB   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Burkitt's lymphoma; CD38; Daratumumab; Macrophage; Multiple myeloma; Phagocytosis; Therapeutic antibody

Indexed keywords

ANTINEOPLASTIC AGENT; CD38 ANTIGEN; DARATUMUMAB; IMMUNOGLOBULIN G1 ANTIBODY; CANCER ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BURKITT LYMPHOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PHAGOCYTOSIS; TUMOR CELL INOCULATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; CELL PHAGOCYTOSIS; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; LYMPHOMA; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; CYTOPHAGOCYTOSIS; HUMANS; LYMPHOMA; MACROPHAGES; MICE; MULTIPLE MYELOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924546237     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1007813     Document Type: Article

References (47)

1. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-54; PMID:12393572; http://dx.doi.org/10.1182/blood- 2002-02-0469
2. Munn DH, McBride M, Cheung NK. Role of lowaffinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res 1991; 51:1117-23; PMID:1825476
3. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25:315-22; PMID:16967326; http://dx.doi.org/ 10.1007/s10555-006-9001-7
4. Ribatti D, Moschetta M, Vacca A. Macrophages in multiple myeloma. Immunol Lett 2014; 161:241-4; PMID:24370642
5. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy druginduced apoptosis. Blood 2009; 114:3625-8; PMID:19710503; http://dx.doi.org/10.1182/blood- 2009-05-220285
6. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20antibody immunotherapy. J Exp Med 2004; 199:1659- 69; PMID:15210744; http://dx.doi.org/10.1084/ jem.20040119
7. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, Haas KM, Tedder TF. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008; 112:1205-13; PMID:18495955; http://dx.doi.org/10.1182/blood- 2008-01-135160
8. McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007; 109:1185-92; PMID:17038522; http://dx.doi.org/10.1182/blood-2006-07-034017
9. Oflazoglu E, Stone IJ, Brown L, Gordon KA, van Rooijen N, Jonas M, Law CL, Grewal IS, Gerber HP. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br J Cancer 2009; 100:113-7; PMID:19066610; http://dx.doi.org/10.1038/sj.bjc.6604812
10. Oflazoglu E, Stone IJ, Gordon KA, Grewal IS, van Rooijen N, Law CL, Gerber HP. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 2007; 110:4370-2; PMID:17909075; http://dx.doi.org/10.1182/blood-2007-06-097014
11. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiplemyeloma. Am J Clin Pathol 2004; 121:482-8; PMID:15080299; http://dx.doi.org/10.1309/74R4TB90BUWH27JX
12. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186:1840-8; PMID:21187443; http:// dx.doi.org/10.4049/jimmunol.1003032
13. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher V, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent anti-tumor activity in models of multiple myeloma and other CD38C hematologic malignancies. Clin Cancer Res 2014; 20:4574-83; PMID:24987056; http://dx. doi.org/10.1158/1078-0432.CCR-14-0695
14. Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, et al. Potent in vitro and in vivo activity of an Fcengineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 2012; 119:2074-82; PMID:22246035; http:// dx.doi.org/10.1182/blood-2011-06-364521
15. Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, et al. Novel anti-B-cell maturation antigen antibodydrug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014; 123:3128-38; PMID:24569262; http://dx.doi.org/10.1182/blood- 2013-10-535088
16. Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, Parren PW. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 2012; 189:3430-8; PMID:22956577; http://dx.doi.org/10.4049/jimmunol.1200356
17. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988; 332:738-40; PMID:3258649; http://dx.doi.org/10.1038/332738a0
18. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164:4178-84; PMID:10754313; http://dx.doi.org/ 10.4049/jimmunol.164.8.4178
19. Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW, Bleeker WK. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011; 187:3383-90; PMID:21832160; http://dx.doi.org/10.4049/ jimmunol.1003926
20. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009; 182:4415-22; PMID:19299742; http://dx.doi.org/10.4049/jimmunol.0713732
21. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12:4027-35; PMID:16818702; http://dx.doi.org/10.1158/1078-0432.CCR-06-0066
22. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98:3383-9; PMID:11719378; http://dx.doi.org/ 10.1182/blood.V98.12.3383
23. Swanson JA, Hoppe AD. The coordination of signaling during Fc receptor-mediated phagocytosis. J Leukoc Biol 2004; 76:1093-103; PMID:15466916; http://dx. doi.org/10.1189/jlb.0804439
24. Paul D, Achouri S, Yoon YZ, Herre J, Bryant CE, Cicuta P. Phagocytosis dynamics depends on target shape. Biophys J 2013; 105:1143-50; PMID:24010657; http://dx. doi.org/10.1016/j.bpj.2013.07.036
25. Oldenborg PA, GreshamHD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 2001; 193:855-62; PMID:11283158; http://dx.doi. org/10.1084/jem.193.7.855
26. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138:271-85; PMID:19632178; http://dx. doi.org/10.1016/j.cell.2009.05.046
27. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2:63ra94; PMID:21178137
28. Martins I, Kepp O, Galluzzi L, Senovilla L, Schlemmer F, Adjemian S, Menger L, Michaud M, Zitvogel L, Kroemer G. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci 2010; 1209:77-82; PMID:20958319; http:// dx.doi.org/10.1111/j.1749-6632.2010.05740.x
29. Subramanian S, Parthasarathy R, Sen S, Boder ET, Discher DE. Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood 2006; 107:2548-56; PMID:16291597; http://dx.doi.org/ 10.1182/blood-2005-04-1463
30. Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI, Dick JE, Danska JS. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 2007; 8:1313-23; PMID:17982459; http://dx.doi.org/10.1038/ni1527
31. Mehta K, Malavasi F. Human CD38 and related molecules. Basel: Karger, SAG; 2000.
32. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, incontrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184:512-20; PMID:19949082; http:// dx.doi.org/10.4049/jimmunol.0900847
33. Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, Bousso P. The mechanism of anti-CD20- mediated B cell depletion revealed by intravital imaging. J Clin Invest 2013; 123:5098-103; PMID:24177426; http://dx.doi.org/10.1172/JCI70972
34. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96:284- 90; PMID:21109694; http://dx.doi.org/10.3324/ haematol.2010.030759
35. Gimsing P, Plesner T, Nahi H, Lokhorst H, Valentin M-L, Lisby S, Richardson PG. A phase I/II, dose-escalation study of daratumumab, a CD38 mab in patients with multiple myeloma - preliminary safety data. ASH Annu Meeting Abstr2011; 118:1873.
36. Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson PG. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I/II study. ASH Annu Meeting Abstr 2012; 120:73.
37. van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2012; 26:199- 213; PMID:21852787; http://dx.doi.org/10.1038/ leu.2011.214
38. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, RoodmanD, Niesvizky R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28:525-42; PMID:24253022; http://dx.doi. org/10.1038/leu.2013.350
39. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24:22-32; PMID:19907437; http://dx.doi.org/10.1038/leu.2009.236
40. Grugan KD, McCabe FL, Kinder M, Greenplate AR, Harman BC, Ekert JE, van Rooijen N, Anderson GM, Nemeth JA, Strohl WR, et al. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J Immunol 2012; 189:5457- 66; PMID:23105143; http://dx.doi.org/10.4049/ jimmunol.1201889
41. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010; 142:699-713; PMID:20813259; http://dx.doi.org/10.1016/j.cell.2010.07.044
42. Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013; 341:88-91; PMID:23722425; http://dx. doi.org/10.1126/science.1238856
43. Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions forma barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 2011; 108:18342-7; PMID:22042861; http://dx.doi.org/10.1073/pnas. 1106550108
44. Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012; 26:2538-45; PMID:22648449; http:// dx.doi.org/10.1038/leu.2012.141
45. Kuipers J, Vaandrager JW, Weghuis DO, Pearson PL, Scheres J, Lokhorst HM, Clevers H, Bast BJ. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet Cytogenet 1999; 109:99-107; PMID:10087940; http://dx.doi.org/10.1016/S0165- 4608(98)00157-5
46. Rozemuller H, van der Spek E, Bogers-Boer LH, Zwart MC, Verweij V, Emmelot M, Groen RW, Spaapen R, Bloem AC, Lokhorst HM, et al. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica 2008; 93:1049-57; PMID:18492693; http://dx.doi.org/ 10.3324/haematol.12349
47. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266:1024-7; PMID:7973652; http://dx.doi.org/10.1126/science.7973652